Search

Your search keyword '"Abbott Laboratories (Abbott Park, Illinois) -- Product information"' showing total 170 results
Start Over Descriptor "Abbott Laboratories (Abbott Park, Illinois) -- Product information"
170 results on '"Abbott Laboratories (Abbott Park, Illinois) -- Product information"'

1. White House outbreak puts tests in spotlight

Author

Alltucker, Ken

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Coronavirus test kits -- Product information, Pharmaceutical industry -- Product information, COVID-19 -- Testing, News, opinion and commentary
Abstract

Byline: Ken Alltucker, USA TODAY The disclosure by President Donald Trump and first lady Melania Trump that they have COVID-19 highlights the role of rapid tests that some say are [...]

Published
2020

2. The White House Uses This Device for Testing. Some Results Might Be False

Author

White, Jeremy and Collins, Keith

Subjects
White House -- Safety and security measures, Abbott Laboratories (Abbott Park, Illinois) -- Product information, ID NOW (Medical instrument) -- Product information -- Usage, Control, Prevention, Usage, Product information, Safety and security measures, Epidemics -- Control -- Prevention -- Product information -- United States, Coronavirus test kits -- Product information -- Usage, Pharmaceutical industry -- Product information -- Usage, COVID-19 -- Prevention -- Product information -- Usage, Coronaviruses, Scientists, Coronavirus infections, Machinery, Infection
Abstract

As the Trump administration scrambles to contain a coronavirus outbreak in the White House, staff members are frequently being tested for the virus. One of the main devices being used [...]

Published
2020

3. Will hyped rapid test deliver?

Author

Heath, David and Penzenstadler, Nick

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, News, opinion and commentary
Abstract

Byline: David Heath and Nick Penzenstadler, USA TODAY President Donald Trump's made-for-TV unboxing of Abbott Laboratories' toaster-sized testing instrument beamed into millions of households last month as he displayed the [...]

Published
2020

4. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial

Author

Clyde, Patrick W., Harari, Amir E., Getka, Eric J., and Shakir, K.M. Mohamed

Subjects
King Pharmaceuticals Inc. -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Synthroid (Medication) -- Evaluation, Cytomel (Medication) -- Evaluation, Hypothyroidism -- Drug therapy, Pharmaceutical industry -- Product information
Abstract

The drug Cytomel may not benefit patients with hypothyroidism who are already taking Synthroid, according to a study of 46 patients. Both of these drugs are synthetic versions of natural thyroid hormone because patients with hypothyroidism do not make enough natural thyroid hormone. In this study, patients who took both drugs had no better outcomes than patients who took Synthroid only.

Published
2003

5. Fenoldapam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial

Author

Stone, Gregg W., McCullough, Peter A., Tumlin, James A., Lepor, Norman E., Madyoon, Hooman, Murray, Patrick, Wang, Andrew, Chu, A. Alan, Schaer, Gary L., Stevens, Melissa, Wilensky, Robert L., and O'Neill, William W.

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Kidney diseases -- Prevention, Contrast media -- Adverse and side effects, Pharmaceutical industry -- Product information
Abstract

The drug fenoldopam mesylate does not prevent kidney disease from becoming worse in patients with kidney disease who must receive a contrast dye during a diagnostic procedure. This was the conclusion of a study of 315 patients at 28 US hospitals. Contrast dyes are used during a diagnostic procedure that involves X-rays to make the X-ray easier to read. Unfortunately, the dye can damage the kidneys.

Published
2003

6. A randomized, clinical trial of oral midazolam plus placebo versus oral midazolam plus oral transmucosal fentanyl for sedation during laceration repair

Author

Klein, Eileen J., Diekema, Douglas S., Paris, Carolyn A., Quan, Linda, Cohen, Morty, and Seidel, Kristy D.

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Fentanyl Oralet (Medication) -- Evaluation, Evaluation, Care and treatment, Injuries, Product information, Pediatric injuries -- Injuries -- Product information -- Care and treatment, Fentanyl -- Evaluation -- Product information -- Product/service Evaluations, Midazolam -- Evaluation -- Product information -- Product/service Evaluations, Wound care -- Product information, Wounds and injuries -- Care and treatment, Children -- Injuries
Abstract

Sedation is often needed for young children undergoing minor procedures in the emergency department (ED). Oral midazolam is a commonly used sedative for children undergoing procedures such as laceration repair. [...], Objective. To determine whether a combination of oral transmucosal fentanyl (Fentanyl Oralet, Abbott Laboratories, North Chicago, IL) plus oral midazolam has an acceptable safety profile and is more effective than oral midazolam alone for sedation during laceration repair in a pediatric emergency department (ED). Methods. Randomized, double-blind, placebo-controlled, clinical trial. Patients between 2 and 8 years of age who weighed >10 kg and presented to the ED with a laceration in need of repair under sedation were eligible for inclusion. All patients received oral midazolam (0.5 mg/kg; maximum dose 10 mg) and either fentanyl (5-10 µg/kg) or placebo in oralet form. Data collected every 5 minutes included the following: heart rate, oxygen saturation, respiratory rate, pain as measured on a Children's Hospital of Eastern Ontario Pain Score (CHEOPS) scale (range: 4-13), and an activity scale (range: 1-5). Effectiveness of sedation was measured by CHEOPS and activity scores compared between the treatment groups. Results. Fifty-one patients were randomized to receive oral midazolam plus fentanyl (N = 28) or oral midazolam plus placebo (N = 23). Age, weight, gender, or baseline pain and activity scores did not differ between the 2 groups. Seven patients in the fentanyl group vomited compared with 0 patients in the placebo group. Three patients in the fentanyl group and no patients in the placebo group had brief oxygen saturation below 93% on room air. The mean pain score within 5 minutes of the start of the procedure did not differ between the 2 groups (fentanyl group, 9.4 versus placebo group, 8.8). Mean activity scores within 5 minutes of the start of the procedure were also similar (fentanyl group, 4.3 versus placebo group, 4.3). Conclusions. The addition of oral transmucosal fentanyl to oral midazolam did not improve pain or activity scores in pediatric patients given sedation for laceration repair. Patients who received Fentanyl Oralet suffered significantly more side effects despite the relatively low doses administered in this study. Oral transmucosal fentanyl should not be used for procedural sedation in the ED. Pediatrics 2002;109:894-897; sedation, Fentanyl Oralet, midazolam.

Published
2002

7. US FDA again stops urokinase sales

Author

Ault, Alicia

Subjects
United States. Food and Drug Administration -- Social policy, Abbokinase (Medication) -- Safety and security measures, Urokinase -- Safety and security measures, Abbott Laboratories (Abbott Park, Illinois) -- Product information
Published
1999

8. Johnson & Johnson Says Prezista Matches Kaletra in HIV Trial

Author

Heltzer, Ned E.

Subjects
Johnson & Johnson -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Anti-HIV agents -- Comparative analysis, Anti-HIV agents -- Dosage and administration, Antiviral agents -- Comparative analysis, Antiviral agents -- Dosage and administration, HIV infection -- Drug therapy, HIV infection -- Research, Health, Kaletra (Medication) -- Dosage and administration, Kaletra (Medication) -- Comparative analysis, Prezista (Medication) -- Dosage and administration, Prezista (Medication) -- Comparative analysis
Abstract

Johnson & Johnson's drug Prezista was as effective as Abbott Laboratories Inc's Kaletra in reducing HIV to undetectable levels in a population of treatment-naive patients, according to a new study [...]

Published
2007

9. Kids on dialysis have new treatment

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Care and treatment, Usage, Product information, Injectable drugs -- Product information -- Usage, dialysis -- Care and treatment, Pharmaceutical industry -- Product information
Abstract

Abbott Laboratories' Zemplar (paricalcitol injection) can now be used in children with kidney disease who have secondary hyperparathyroidism (SHPT). Previously the product was approved for adult SHPT patients. SHPT develops [...]

Published
2004

10. Divalproex extended-release tablets

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Depakote (Medication) -- Dosage and administration -- Product information, Care and treatment, Product information, Dosage and administration, Pediatric epilepsy -- Care and treatment -- Product information, Anticonvulsants -- Dosage and administration -- Product information, Valproic acid -- Dosage and administration -- Product information, Pharmaceutical industry -- Product information, Epilepsy in children -- Care and treatment -- Product information, Divalproex -- Dosage and administration -- Product information
Abstract

Divalproex extended-release tablets (Depakote ER, Abbott) received FDA approval for use in children aged 10 years or older with epilepsy. Specifically, the drug is approved as once-daily dosing for the [...]

Published
2003

11. Synthroid passes muster; now it's digoxin's turn. (Latelines)

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, United States. Food and Drug Administration -- Standards, Synthroid (Medication) -- Standards -- Usage -- Product information, Drug therapy, Standards, Usage, Product information, Thyroid diseases -- Drug therapy -- Product information -- Usage, Pharmaceutical industry -- Product information -- Standards -- Usage
Abstract

Abbott Laboratories' Synthroid (levothyroxine sodium tablets, USP) has finally received FDA approval, after being on the market for almost half a century. The FDA required the manufacturer to file an [...]

Published
2002

12. Depakote, Depakene. (Safety labeling updates & new warnings)

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Depakene (Medication) -- Labeling -- Product information, Depakote (Medication) -- Labeling -- Product information, Labeling, Product information, Pharmaceutical industry -- Product information
Abstract

Patients with known or suspected urea cycle disorders (UCDs) should not take epilepsy drug. Abbott Laboratories has revised labeling for all dosage forms of valproic acid (Depakote, Depakene) to highlight [...]

Published
2002

13. Diet drug on hot seat. (Latelines)

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Product information, Causes of, Death -- Causes of -- Product information, Drugs -- Product information, Pharmaceutical industry -- Product information
Abstract

Public Citizen has petitioned the FDA to pull Abbott Laboratories' Meridia (sibutramine) from the market. The consumer advocacy group said the diet drug has not only caused some deaths but [...]

Published
2002

14. Abbott gets Synthroid NDA in before deadline

Author

Dickinson, James G.

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, United States. Food and Drug Administration -- Powers and duties, Powers and duties, Product information, Drugs -- Product information, Pharmaceutical industry -- Product information
Abstract

Two weeks in advance of an FDA-imposed deadline that would have required the company to pull its product off the market, Abbott Laboratories in July submitted a New Drug Application [...]

Published
2001

15. LOPPINAVIR/RITONAVIR

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Business, Chemicals, plastics and rubber industries
Abstract

Abbott Laboratories has been granted Canadian regulatory approval to market Kaletra (lopinavir/ritonavir), its new protease inhibitor for the treatment of HIV infection in combination with other antiretroviral [...]

Published
2001

16. There's Room for All in Nutrition

Subjects
Heinz U.S.A. -- Product information, Mead Johnson Nutritionals -- Product information, Novartis Consumer Health Inc. -- Product information, Beech-Nut Foods Corp. -- Product information, PTS Labs L.L.C. -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Dietary supplements industry -- Product information, Baby foods industry -- Product information, Infants' supplies industry -- Product information, Dairy industry -- Product information, Drugs -- Product information, Pharmaceutical industry -- Product information, Business, Retail industry
Abstract

INFANT CARE NEW YORK-- Infant nutrition is a big and growing segment of the baby care business, with annual sales close to $4 billion. It is also a field dominated [...]

Published
2000

17. Valproate

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Depakote (Medication) -- Labeling -- Product information, Labeling, Risk factors, Product information, Psychotropic drugs -- Product information, Pancreatitis -- Risk factors -- Product information
Abstract

A new warning on pancreatitis has been added to labeling for valproate (Depakote) in tablet, capsule, injection and syrup forms. In a recent 'Dear Health Professional' letter, Abbott Laboratories advised [...]

Published
2000

18. Black Box Warning Label Added to Valproate Products

Author

Tucker, Miriam E.

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Labeling, Product information, Drugs -- Product information -- Labeling, Valproic acid -- Labeling -- Product information, Pharmaceutical industry -- Product information, Divalproex -- Labeling -- Product information
Abstract

A black box warning about the possibility of life-threatening pancreatitis has been added to the labels of Depakote, Depakene, and Depacon. Although the package inserts of all valproate products have [...]

Published
2000

19. Abbott warns of pancreatitis risk

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Depakene (Medication) -- Product information, Depakote (Medication) -- Product information, Depacon (Medication) -- Product information, Complications and side effects, Risk factors, Product information, Pancreatitis -- Risk factors -- Complications and side effects -- Product information, Drugs -- Complications and side effects -- Product information, Pharmaceutical industry -- Product information
Abstract

Abbott has issued a warning about life-threatening pancreatitis in adults and children receiving Depakote Tablets (divalproex sodium delayed-release tablets), Depakote Sprinkle Capsules (divalproex sodium coated particles in capsules), Depacon (valproate [...]

Published
2000

20. NEW FORMULATIONS

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Product information, Antibiotics -- Product information, Pharmaceutical industry -- Product information
Abstract

Abbott Laboratories, Abbott Park, Ill., (800) 255-5162, has received FDA approval to market Biaxin XL (clarithromycin extended-release tablets). The new once-daily formulation of the company's widely prescribed macrolide antibiotic tablets [...]

Published
2000

21. Abbott Laboratories

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Soybean industry -- Product information, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

A single serving of Abbott Laboratories' Health Source offers 80 percent of the 25 grams of soy protein a day cited in the FDA's recent ruling. In addition, the soy [...]

Published
1999

22. ABBOTT LABORATORIES

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Mcdimmune -- Product information, Pharmaceutical industry -- Product information, Business, Chemicals, plastics and rubber industries
Abstract

ABBOTT LABORATORIES and Mcdimmune have received European marketing approval for Synagis (palivizumab), a monoclonal antibody for treating respiratory syncytial [...]

Published
1999

23. Reformulated Ritonavir Capsule Approved

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Ritonavir -- Dosage and administration, HIV infection -- Drug therapy, Health
Published
1999

24. Abbott gets FDA approval for reformulated Norvir capsule

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

Abbott Laboratories has received FDA approval for Norvir (ritonavir) soft-gelatin capsules. Norvir is a protease inhibitor indicated in combination with other anti-retroviral medications for the treatment of HIV infection. The [...]

Published
1999

25. RITONAVIR

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Business, Chemicals, plastics and rubber industries
Abstract

Abbott Laboratories has received FDA approval for a soft-gelatin capsule formulation of Norvir (ritonavir), a protease inhibitor for the treatment of HIV infection in combination with other anti-retroviral medications. The [...]

Published
1999

26. Treatment for Breakthrough Cancer Pain Approved

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Cancer -- Drug therapy, Pharmaceutical industry -- Product information, Health, Actiq (Medication) -- Evaluation
Abstract

The authors reports on the FDA approval of a drug for cancer pain management. Information regarding usage, background, and limitations of the drug Actiq are examined.

Published
1999

27. Humira

Subjects
Humira (Medication) -- Product information, Rheumatoid arthritis -- Drug therapy, Pharmaceutical industry -- Product information, Anti-inflammatory drugs -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- Product information
Published
2005

28. Can Abbott restock its cabinet? Humira is a bona fide hit, but the company's drug pipeline is drying up

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Company sales and earnings, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Product information, Company earnings/profit, Business, Business, regional, Humira (Medication) -- Research, Humira (Medication) -- Product information
Abstract

Abbott Laboratories' blockbuster rheumatoid arthritis drug Humira helps tens of thousands of victims of the debilitating disease, but it can't prop up the drugmaker's earnings forever. In just three years [...]

Published
2006

29. Cholesterol management with fibrate, statin

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Fenofibrate -- Licensing, certification and accreditation, Hypercholesterolemia -- Drug therapy, Pharmaceutical industry, Health
Published
2009

30. European Union clears Humira for adult rheumatoid arthritis

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Laws, regulations and rules, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- International trade, Pharmaceutical industry -- Product information, Pharmaceutical industry -- Laws, regulations and rules, Pharmaceutical industry -- International trade, Government regulation, Business, Business, general, Humira (Medication) -- Laws, regulations and rules, Humira (Medication) -- International trade
Published
2003

31. Abbott halts trial of prostate cancer drug

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Atrasentan (Medication) -- Testing -- Product information, Pharmaceutical industry -- Product information
Abstract

The health care products maker Abbott Laboratories Inc. said yesterday that it had scrapped a clinical trial of its new drug for prostate cancer because the drug failed to halt […]

Published
2003

32. Laboratories scramble to find replacement supplies following FDA ban on 125 Abbott products

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Medical test kits -- Safety and security measures, Business, Health care industry, Pharmaceuticals and cosmetics industries
Abstract

The impact of the FDA's decision to withdraw over 125 diagnostics products made by Abbott Laboratories from the market, is assessed.

Published
1999

33. Showdown Looms Over Arthritis Medications; With Humira, Abbott Laboratories plans to give real competition to Amgen's popular but hard-to-get treatment Enbrel

Author

Gellene, Denise

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Amgen Inc. -- Product information, Pharmaceutical industry, Rheumatoid arthritis -- Drug therapy, Product marketing strategy, Cooperative agreement for product distribution, Company product acquisition, Company product planning, Product market share, Product installation, Product distribution, General interest, News, opinion and commentary, Humira (Medication) -- Product information, Enbrel (Medication) -- Supply and demand, Enbrel (Medication) -- Product information
Published
2002

34. FDA approves Abbott's Synthroid

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Business, Business, general, Synthroid (Medication) -- Laws, regulations and rules
Published
2002

35. European Union says Abbott's obesity drug doesn't pose a risk

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Weight reducing preparations -- Health aspects, Business, Business, general, Meridia (Medication) -- Health aspects
Published
2002

36. Abbott's biotech search; Counting on partnerships, wonder drugs

Author

Klein, Sarah A.

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Business, Business, regional
Abstract

Abbott Laboratories, which for years has hovered near the bottom of the pharmaceutical industry's top-10 international rankings, is now banking on a handful of biotech breakthroughs to leapfrog into the [...]

Published
2002

37. Filing is submitted to FDA for Synthroid thyroid drug

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Hypothyroidism -- Drug therapy, Business, Business, general, Synthroid (Medication) -- Laws, regulations and rules
Published
2001

38. Filing is submitted to FDA for Synthroid thyroid drug

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Business, Business, general, Synthroid (Medication) -- Laws, regulations and rules
Published
2001

39. Longtime Drug's New Troubles; Synthroid, taken by 8 million people with thyroid problems, is under FDA scrutiny

Author

Roan, Shari

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Laws, regulations and rules, Drug approval -- Laws, regulations and rules, Thyroid diseases -- Drug therapy, General interest, News, opinion and commentary, Synthroid (Medication) -- Laws, regulations and rules
Published
2001

41. Second H. pylori dual ulcer therapy heads for market

Author

Pfeiffer, Naomi

Subjects
Glaxo Wellcome PLC -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Biaxin (Medication) -- Usage -- Product information, Tritec (Medication) -- Usage -- Product information, Care and treatment, Usage, Product information, Antiulcer agents -- Usage -- Product information, Antibiotics -- Usage -- Product information, Clarithromycin -- Usage -- Product information, Pharmaceutical industry -- Product information, Duodenal ulcer -- Care and treatment -- Product information, Antiulcer drugs -- Usage -- Product information
Abstract

Second H. pylori dual ulcer therapy heads for market Tritec (ranitidine bismuth citrate, Glaxo Wellcome), to be taken together with Biaxin (clarithromycin, Abbott), has received Food & Drug Administration marketing [...]

Published
1996

42. Warning on anticlot drug issued, allowing shipments

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Business, Business, general, Abbokinase (Medication) -- Safety and security measures
Published
1999

43. Oralet's US distribution restricted

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Pharmaceutical industry -- Product information, Anesthetics -- Distribution, Business, Pharmaceuticals and cosmetics industries, Oralet (Medication) -- Distribution
Published
1994

44. Protease inhibitors may cause diabetes, U.S. agency warns

Subjects
Merck & Company Inc. -- Product information, Hoffmann-La Roche Inc. -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Agouron Pharmaceuticals Inc. -- Product information, Protease inhibitors -- Health aspects, Diabetes -- Causes of, AIDS (Disease) -- Drug therapy, Business, Business, general
Published
1997

45. FDA approves AIDS drugs for treating children

Author

Ingersoll, Bruce

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Abbott Laboratories (Abbott Park, Illinois) -- Product information, Agouron Pharmaceuticals Inc. -- Product information, Protease inhibitors -- Laws, regulations and rules, Pharmaceutical industry -- Product information, Business, Business, general, Viracept (Medication) -- Laws, regulations and rules, Norvir (Medication) -- Laws, regulations and rules
Published
1997

46. Blood glucose monitoring: Abbott Animal Health

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Veterinary supplies industry -- Product information, Blood sugar monitoring -- Product information, Health, Zoology and wildlife conservation, Alpha Trak Blood Glucose Monitoring System (Medical test kit)
Abstract

The AlphaTrak[R] Blood Glucose Monitoring System is calibrated for cats, dogs, ferrets and horses and can produce results equivalent to those from a reference method. Results are available in seconds, [...]

Published
2010

47. For first time, drug 'cocktail' seems to eliminate HIV in its hiding places

Author

Waldholz, Michael

Subjects
Glaxo Wellcome PLC -- Product information, Abbott Laboratories (Abbott Park, Illinois) -- Product information, HIV (Viruses) -- Drug therapy, Protease inhibitors -- Research, Pharmaceutical industry -- Product information, Business, Business, general
Published
1996

49. Product: Trilipix

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Product information, Trilipix (Medication) -- Dosage and administration -- Complications and side effects -- Product information, Complications and side effects, Product information, Dosage and administration, Fibric acids -- Dosage and administration -- Complications and side effects -- Product information, Pharmaceutical industry -- Product information
Abstract

PRODUCT: Trilipix COMPANY: Abbott PHARMACOLOGIC CLASS: Fibrate ACTIVE INGREDIENTS: Fcnofibric acid (as choline fenofibrate) 45mg, 135mg; del-rel caps. INDICATIONS: Adjunct to diet: In combination with a statin, to reduce triglycerides [...]

Published
2009

50. Pressure group calls for recall of urokinase

Author

Ault., Alicia

Subjects
Public Citizen -- Reports, Urokinase -- Adverse and side effects, Pharmaceutical industry -- Safety and security measures, Abbott Laboratories (Abbott Park, Illinois) -- Product information, BioWhittaker Inc. -- Product information
Published
1999

Catalog

Books, media, physical & digital resources
See catalog results